US 11,986,483 B2
Otic formulations, methods and devices
Douglas I. Hepler, Overland Park, KS (US); Gail L. Dempsey, Overland Park, KS (US); Dorothea A. Erxleben, Overland Park, KS (US); and Neil E. Paulsen, Overland Park, KS (US)
Assigned to Dechra Veterinary Products, LLC, Overland Park, KS (US)
Filed by Dechra Veterinary Products, LLC, Overland Park, KS (US)
Filed on Oct. 8, 2020, as Appl. No. 17/066,343.
Claims priority of provisional application 62/914,301, filed on Oct. 11, 2019.
Prior Publication US 2021/0106597 A1, Apr. 15, 2021
Int. Cl. A61K 31/573 (2006.01); A61D 7/00 (2006.01); A61K 9/00 (2006.01); A61K 31/137 (2006.01); A61K 31/4174 (2006.01); A61K 31/5395 (2006.01); A61K 31/56 (2006.01); A61K 31/58 (2006.01); A61K 47/44 (2017.01); A61M 31/00 (2006.01); A61P 27/16 (2006.01); A61P 31/00 (2006.01)
CPC A61K 31/573 (2013.01) [A61D 7/00 (2013.01); A61K 9/0046 (2013.01); A61K 31/137 (2013.01); A61K 31/4174 (2013.01); A61K 31/5395 (2013.01); A61K 31/56 (2013.01); A61K 31/58 (2013.01); A61K 47/44 (2013.01); A61M 31/00 (2013.01); A61P 27/16 (2018.01); A61P 31/00 (2018.01); A61M 2210/0662 (2013.01)] 16 Claims
 
1. An otic formulation comprising:
a) therapeutic agents consisting of:
i) about 1.5% to 1.9% w/w of marbofloxacin;
ii) about 1.6% to 2.0% w/w of terbinafine or salts thereof; and
iii) about 0.1% to 0.25% w/w of dexamethasone; wherein the formulation further comprises
b) about 78% to 80% w/w mineral oil; and
c) about 17% to 18% w/w paraffin.